Amgen reports fiscal Q4 2025 results: revenue $9.87B, up 9% from a year earlier

Amgen filed a Form 8-K with the SEC on Feb 3, 2026, 4:03 PM ET, reporting an event dated Feb 3, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q4 2025 (quarter ended Dec 31, 2025); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $9.87B (+8.6% from $9.09B a year earlier) [derived from annual minus nine-month figures]
• Operating income: $2.72B (+17.7% from $2.31B a year earlier) [derived from annual minus nine-month figures]
• Net income: $1.33B (+112.6% from $627.0M a year earlier) [derived from annual minus nine-month figures]
• Diluted EPS: $2.46 (+112.1% from $1.16 a year earlier) [derived from annual minus nine-month figures]
• Form 8-K accepted by EDGAR Feb 3, 2026, 4:03 PM ET
• Accession number 0000318154-26-000003

SEC filing 8-K · accession 0000318154-26-000003 · sec.gov ↗